Core Insights - Edwards Lifesciences (EW) has achieved a remarkable 22.1% return over the past year, significantly outperforming the industry's decline of 3.8% and closely aligning with the S&P 500's rise of 23.5% [1][8] Company Performance - The company is currently ranked 2 (Buy) by Zacks and has shown consistent growth in the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment, while effectively scaling its fast-growing businesses [2] - The Transcatheter Aortic Valve Replacement (TAVR) platform has benefited from technological advancements like RESILIA and increased global adoption, with TAVR sales exceeding $1 billion for the fifth consecutive quarter [2][6] - The Surgical Structural Heart business is experiencing robust uptake of premium surgical technologies globally, contributing to overall growth [2][10] Recent Developments - On September 3, 2024, Edwards completed the sale of its Critical Care product group to Becton, Dickinson, and Company for $4.2 billion, enhancing its balance sheet flexibility for investments in new technologies [3] - The company has seen strong momentum in the TMTT segment, driven by the global adoption of PASCAL and EVOQUE systems, which provide solutions for mitral and tricuspid patients [4][8] - The EVOQUE system became eligible for all Medicare beneficiaries with symptomatic tricuspid regurgitation in March 2025, and the SAPIEN M3 mitral valve replacement system received CE Mark approval in April 2025 [5] Financial Estimates - The Zacks Consensus Estimate projects a 14.8% increase in earnings per share (EPS) for 2026 to $2.94 and a 12.2% increase for 2027 to $3.30, with revenues expected to grow 9.6% to $6.65 billion in 2026 and 9.8% to $7.30 billion in 2027 [12]

Core Insights - Edwards Lifesciences Corporation reported fourth-quarter 2025 adjusted earnings per share (EPS) of 58 cents, missing the Zacks Consensus Estimate by 5.89% and reflecting a 1.7% year-over-year decline [1] - Full-year adjusted EPS was $2.56, a 5.3% increase from 2024, but also missed the Zacks Consensus Estimate by 1.2% [2] Revenue Performance - Total sales for the fourth quarter reached $1.57 billion, marking a 13.3% year-over-year increase and surpassing the Zacks Consensus Estimate by 1.99% [3] - Full-year revenues for 2025 amounted to $6.07 billion, up 11.5% year over year, also beating the Zacks Consensus Estimate by 0.7% [3] Segment Sales Analysis - Transcatheter Aortic Valve Replacement (TAVR) sales were $1.16 billion, up 12% year over year, driven by increased focus on SAPIEN therapy [4] - Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached $155.7 million, a significant 48.3% increase from the prior year, exceeding projections [5] - Surgical Structural Heart sales totaled $253.6 million, reflecting a 3.8% year-over-year growth despite some inventory adjustments [6] Margin and Cost Analysis - Gross profit was $1.22 billion, a 12.2% increase year over year, but gross margin contracted by 77 basis points to 78.2% due to a 17.4% rise in cost of sales [7] - Selling, General and Administrative (SG&A) expenses rose 22.6% year over year to $602.9 million, while R&D expenditures decreased by 1.3% to $267.7 million [7] Future Guidance - For 2026, the company projects sales growth of 8% to 10%, with adjusted EPS expected in the range of $2.90 to $3.05 [11] - The first quarter of 2026 is projected to have total sales between $1.55 billion and $1.63 billion, with adjusted EPS in the range of 70 to 76 cents [12] Overall Performance Summary - Despite an earnings miss, Edwards Lifesciences experienced revenue growth and expressed confidence in its 2026 outlook, supported by strong quarterly performance and ongoing adoption of its therapies [13]

Core Viewpoint - Edwards Lifesciences Corp. is expected to report strong fourth-quarter 2025 results, with revenue and earnings estimates indicating significant year-over-year growth [1][9]. Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for revenues is $1.54 billion, reflecting an 11.1% increase from the previous year [2]. - The earnings estimate is set at 62 cents per share, indicating a 5.1% rise from the year-ago figure [2]. - The company has consistently beaten earnings estimates in the past four quarters, with an average surprise of 8.89% [1]. Group 2: Segment Performance - The Transcatheter Aortic Valve Replacement (TAVR) segment is projected to generate $1.13 billion in sales, representing an 8.6% year-over-year increase, driven by strong performance and clinical community focus [6][9]. - The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment is expected to see revenues of $151.6 million, implying a 44.2% improvement from the previous year, supported by the PASCAL, EVOQUE, and SAPIEN M3 systems [10][9]. - The Surgical Structural Heart segment is estimated to generate $259.8 million, suggesting a modest 6.3% rise from the year-ago quarter, aided by the global adoption of the RESILIA portfolio [12][11]. Group 3: Market Trends and Guidance - Edwards has raised its 2025 sales growth guidance for the TAVR segment to 7-8%, up from the previous 6-7% [6]. - The company is expected to benefit from global procedure growth and expanded education in the TAVR market, particularly in the U.S. [4][5]. - The recent FDA approval of the SAPIEN M3 mitral valve replacement system is anticipated to contribute positively to the company's top-line growth [8].

Core Insights - Edwards Lifesciences Corp. (EW) is set to report its third-quarter 2025 results on October 30, after market close [1][9] - The company’s adjusted earnings per share for the last quarter were 67 cents, exceeding the Zacks Consensus Estimate by 8.06%, with an average surprise of 5.50% over the past four quarters [1] Q3 Estimates - The Zacks Consensus Estimate for revenues is $1.50 billion, indicating an 11.5% growth from the previous year [2] - The earnings estimate is 59 cents per share, reflecting an 11.9% decline from the year-ago figure [2][3] Performance Factors - The Transcatheter Aortic Valve Replacement (TAVR) segment is expected to perform strongly in the U.S., driven by the SAPIEN 3 Ultra RESILIA platform, with projected sales of $1.11 billion, an 8.5% year-over-year increase [4][5][9] - The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment is anticipated to report revenues of $134.1 million, a 47.2% increase from the previous year, supported by the PASCAL repair system and the EVOQUE tricuspid replacement system [6][7][9] - The Surgical Structural Heart segment is estimated to generate revenues of $256.7 million, reflecting a 7% rise from the year-ago quarter, aided by the global adoption of the RESILIA portfolio [10] Earnings Expectations - Edwards has an Earnings ESP of +0.47%, indicating a higher likelihood of beating estimates [11] - The company currently holds a Zacks Rank of 3, suggesting a neutral outlook [12]

Core Insights - Edwards Lifesciences Corporation reported Q2 2025 adjusted EPS of 67 cents, exceeding estimates by 8.1% and reflecting an 8.1% year-over-year increase [1] - Total sales reached $1.53 billion, up 11.7% year-over-year, surpassing estimates by 2.7% [2] - The company raised its 2025 sales growth forecast to 9-10% and adjusted EPS guidance to the high end of $2.40-$2.50 [11][12] Q2 Sales Performance - Sales from Transcatheter Aortic Valve Replacement (TAVR) totaled $1.10 billion, an increase of 8.9% year-over-year [3] - Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached $134.5 million, up 61.9% from the previous year [5] - Surgical Structural Heart segment sales were $267 million, reflecting a 7.7% year-over-year increase [6] Margin and Expense Analysis - Gross profit was $1.19 billion, up 8.6% year-over-year, but gross margin contracted by 236 basis points to 77.5% due to a 25% rise in cost of sales [7] - SG&A expenses rose 12.2% year-over-year to $502 million, while R&D expenditures increased by 1.6% to $276.2 million [9] Cash Position and Debt - The company ended Q2 with cash and cash equivalents of $3.00 billion, down from $3.10 billion at the end of Q1 2025, with total debt remaining around $600 million [10] Market Dynamics and Innovations - Clinical discussions around EARLY TAVR trial data are enhancing patient management for severe aortic stenosis in the U.S. [4] - The exit of a competitor in Europe has positively impacted Edwards' market share [4] - The SAPIEN M3 mitral valve replacement system received CE Mark approval, strengthening the TMTT portfolio [14]

Core Insights - Edwards Lifesciences is experiencing strong growth in its premium surgical technologies, particularly in the TAVR platform, which is expected to maintain global leadership and sustainable growth [1][9] - The company is also benefiting from a strategic portfolio in Transcatheter Mitral and Tricuspid Therapies, although macroeconomic challenges and currency fluctuations pose risks to its operations [1][9] Financial Performance - Over the past year, Edwards Lifesciences' stock has declined by 11.2%, compared to a 12.9% decline in the industry and a 13.1% growth in the S&P 500 [2] - The company has a market capitalization of $44.66 billion and an earnings yield of 3.2%, which is favorable compared to the industry's -3.6% [2] - In the last four quarters, Edwards surpassed earnings estimates twice and matched on two occasions, with an average surprise of 3.5% [2] Business Segments - The Surgical Structural Heart segment grew by 1% year-over-year in Q1 2025, driven by the adoption of premium surgical technologies like INSPIRIS, MITRIS, and KONECT [4] - TAVR sales exceeded $1 billion for the second consecutive quarter, with strong performance from SAPIEN 3 Ultra RESILIA in the U.S. and Europe [6][9] - The TMTT segment saw a 58% increase in sales in Q1, driven by the adoption of the PASCAL and EVOQUE systems [9][11] Innovations and Developments - Edwards launched the MITRIS system in China, receiving positive feedback from surgeons [5] - The acquisition of Endotronix in 2024 marks the company's entry into implantable heart failure management [5] - The SAPIEN M3 mitral valve replacement system received CE Mark for treating symptomatic mitral regurgitation patients unsuitable for surgery [12] Challenges - The company faces macroeconomic pressures, including inflation, credit market conditions, and geopolitical complications, which are impacting operating results [13] - Foreign exchange fluctuations are a significant headwind, with a 170 basis point decrease in reported sales growth attributed to unfavorable currency impacts [14]